Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexsotalol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 1.00 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 0.97 |
| ▸ | GLA | P06280 | 1/20 | 0.97 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MTOR | P42345 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sotalol SCHEMBL16407 | 1.00 | ADRB3 (1.00) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL29761416 | 1.00 | ADRB3 (1.00) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL6508618 | 1.00 | ADRB3 (1.00) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL118761 | 0.98 | ADRB3 (1.00) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Dexsotalol SCHEMBL5661932 | 0.98 | ADRB3 (1.00) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL20575697 | 0.98 | ADRB3 (1.00) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL3127442 | 0.97 | ADRB3 (0.94) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL3287528 | 0.97 | ADRB3 (0.94) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL1649808 | 0.97 | ADRB3 (0.94) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL29188242 | 0.92 | ADRB3 (0.84) | ADRB3LMNAADRB2ADRB1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2529 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-20250264469-A1 | METHODS FOR IMPROVING OUTCOMES FOR HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AT RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER | 2025-08-21 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20240033258-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY & AGRICULTURAL & MECHANICAL COLLEGE (US) | 2024-02-01 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2023212288-A1 | METHODS FOR IMPROVING OUTCOMES FOR HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AT RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230174641-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | H LUNDBECK AS (DK) | 2023-06-08 | — | — | US | claimed |
| US-20220333169-A1 | Polygenic Score for Cardiac Heart Failure | HENRY FORD HEALTH SYSTEM (US) | 2022-10-20 | — | — | US | claimed |
| EP-4066850-A2 | PEPTIDES AND METHODS OF TREATING DYSTROPHY-RELATED DISORDERS USING THE SAME | Bioincept LLC (US) | 2022-10-05 | — | — | EP | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| WO-2005097087-A2 | MERGED ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2005-10-20 | — | — | WO | claimed |
| EP-1555019-A1 | Pharmacologic drug combination in vagal-induced asystole | Emory University (US) | 2005-07-20 | — | — | EP | claimed |
| EP-1183011-A4 | METHOD OF TREATING ANGINA AND/OR ANGINAL EQUIVALENTS, AND PHARMACEUTICAL COMPOSITIONS AND KIT RELATED THERETO | ESPERION LUV DEV INC (US) | 2005-01-19 | — | — | EP | claimed |
| JP-2003508349-A | — | — | 2003-03-04 | — | — | JP | claimed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | claimed |
| EP-1183011-A1 | METHOD OF TREATING ANGINA AND/OR ANGINAL EQUIVALENTS, AND PHARMACEUTICAL COMPOSITIONS AND KIT RELATED THERETO | Esperion Mergerco, Inc. (US) | 2002-03-06 | — | — | EP | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| WO-2000069412-A1 | METHOD OF TREATING ANGINA AND/OR ANGINAL EQUIVALENTS, AND PHARMACEUTICAL COMPOSITIONS AND KIT RELATED THERETO | ESPERION LUV DEVELOPMENT, INC. (US) | 2000-11-23 | — | — | WO | claimed |
| US-5484776-A | REACTION WITH POLYSACCHARIDE | SYNEPOS AKTIENGESELLSCHAFT (LI) | 1996-01-16 | — | — | US | claimed |